🇺🇸 FDA
Patent

US 12377068

In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

granted A61KA61K31/343A61K31/352

Quick answer

US patent 12377068 (In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors) held by Provectus Pharmatech, Inc. expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Provectus Pharmatech, Inc.
Grant date
Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/343, A61K31/352, A61K31/365, A61K31/4745